Press Release: Vidac Pharma : Vidac Pharma is proud to announce Clinical Trial Approval in Germany following CTIS update
The trial will test Vidac's first-in-class therapy reversing the Warburg effect to treat high-risk actinic keratosis lesions Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, November 4, 2025 /EINPresswire ...
Read full article »
Vidac Pharma develops medicines to help people suffering from oncologic and dermatologic medical conditions.
Read more